Table 1.
Treatment, response to chemotherapy and outcome in 15 patients with prostatic stromal sarcoma (14 from the English literature and the case we described).
| Ref. (year) | Age | Tumor extension | Treatment | Drugs (cycles) | Rsponse to CT | Outcome | ||
|---|---|---|---|---|---|---|---|---|
| First-line | Second-line | |||||||
| 1 | 2 (1998) | 25 | Prostate | RCP, adjuvant CTh | n.r. | n.r. | NED 12 mo after RP | |
| 2 | 2 (1998) | 59 | Prostate | RCP, RT, adjuvant CTh | n.r. | n.r. | LR, AWD 72 mo after Dx | |
| 3 | 15 (2001) | 36 | Prostate extending to neck of bladder | RP | Neoadjuvant CTh + RT (70 Gy/35 f) | DOXO + IFO (6) | PR | LR, DOD 20 mo after Dx |
| 4 | 6 (2002) | 35 | Prostate, pelvic walls | RP+RT (60 Gy) | Neoadjuvant CTh + lobectomy | DOXO + IFO (5) | PR | DR (lung), NED 5 mo after lobectomy |
| 5 | 7 (2003) | 78 | Prostate extending to bladder, abdominal walls | RP+ adjuvant CTh | VCR + MMCO + DOX + CDDP (6) | n.r. | DR (liver), DOD 6 mo after CTh | |
| 6 | 17 (2006) | 19 | Prostate | RP | Neoadjuvant CTh+ RT (49.2 Gy) | VP-16 + IFO +CDDP (4) | PR | LR, NED 48 mo after CTh and RT |
| 7 | 11 (2006) | 75 | Prostate extending to seminal vesicles | Enucleation, RT, adjuvant CTh | n.r. | n.e. | NED 13 mo after Dx | |
| 8 | 19 (2007) | 52 | Prostate | RCP | Neoadjuvant CTh + metastasectomy | CDDP + PIRA + IFO (3) | n.r. | LR, AWD 12 mo after metas-tasectomy |
| 9 | 22 (2010) | 31 | Prostate | Neoadjuvant C Th + RP | Cstectomy | IFO + DOXO (2) | SD | LR, DOD 3 mo after cystectomy |
| 10 | 5 (2010) | 34 | Prostate | RP+RT (60 Gy) | Lung metastasectomy + palliative RT and CT | IFO + DOXO h | PR | LR, DR (lung), PD, DOD 25 mo after Dx |
| 11 | 4 (2010) | 30 | Prostate extending to bladder, anterior bowel walls, lungs | Neoadjuvant CTh + RT (still ongoing) | n.r. | n.e. | n.r. | |
| 12 | 23 (2011) | 26 | Prostate, lymph nodes | Neoadjuvant CTh | n.r. | PD | DR (mediastinal lymph node), DOD 7 mo after Dx | |
| 13 | 21 (2012) | 63 | Prostate extending to bladder | Neoadjuvant CTh + total pelvic exenteration | CDDP + CPT-11 | n.r. | NED at 16 mo after RCP | |
| 14 | 24 (2012) | 66 | Prostate extending to bladder | Subtotal P + neoadjuvant CTh + RT (50 Gy) + RCP | IFO + DOXO (2) | n.e. | n.r. | |
| 15 | Present case | 14 | Prostate extending to bladder, seminal vesicles, lymph nodes, bone | Neoadjuvant CTh + RT (50 Gy) + RCP | IFO + VCR + ACT +DOXO (9) | PR | PD, DOD 15 mo after Dx | |
ACT, actinomycin; AWD, alive with disease; CDDP, cisplatin; CPT-11, irinotecan; CTh, chemotherapy; DOD, dead of disease; DOXO, doxorubicin; DR, distant recurrence; Dx, diagnosis; IFO, ifosfamide; Gy, Gray; LR, local recurrence; MMC, mitomycin C; mo, months; n.e., not evaluable; NED, no evidence of disease; n.r., not reported; P, prostatectomy; PD, progression of disease; PIRA; pirarubicin; PR, partial response; RCP, radical cystoprostatectomy; RP, radical prostatectomy; RT, radiotherapy; SD, stable disease; VCR, vincristine; VP-16, etoposide.